Spero Therapeutics (SPRO) Stock Overview
A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SPRO Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Spero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.38 |
| 52 Week High | US$3.22 |
| 52 Week Low | US$0.51 |
| Beta | 1.46 |
| 1 Month Change | 25.93% |
| 3 Month Change | 9.43% |
| 1 Year Change | 81.68% |
| 3 Year Change | 20.81% |
| 5 Year Change | -83.18% |
| Change since IPO | -79.30% |
Recent News & Updates
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Oct 29
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
Aug 13Recent updates
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Oct 29Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
Aug 13Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Jul 16Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
Jun 11
Successful Phase III Trial Will Redefine Treatment For Complicated UTIs
Successful PIVOT-PO trial and regulatory approval could propel revenue growth, leveraging a strategic partnership with GSK for commercialization.Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Feb 04Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Jan 19There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Nov 02Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Jul 15Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10Shareholder Returns
| SPRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.2% | 2.1% |
| 1Y | 81.7% | 3.9% | 18.7% |
Return vs Industry: SPRO exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: SPRO exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| SPRO volatility | |
|---|---|
| SPRO Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SPRO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SPRO's weekly volatility has decreased from 36% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 32 | Esther Rajavelu | sperotherapeutics.com |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.
Spero Therapeutics, Inc. Fundamentals Summary
| SPRO fundamental statistics | |
|---|---|
| Market cap | US$128.87m |
| Earnings (TTM) | -US$53.60m |
| Revenue (TTM) | US$48.58m |
Is SPRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRO income statement (TTM) | |
|---|---|
| Revenue | US$48.58m |
| Cost of Revenue | US$79.98m |
| Gross Profit | -US$31.40m |
| Other Expenses | US$22.20m |
| Earnings | -US$53.60m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -64.65% |
| Net Profit Margin | -110.34% |
| Debt/Equity Ratio | 0% |
How did SPRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 11:08 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spero Therapeutics, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Joshua Schimmer | Evercore ISI |